SCHEMBL6972765

SCHEMBL6972765

Fc1cccc2ncsc12

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.45
HSD17B10 Q99714 1/20 0.45
PARP1 P09874 3/20 0.35
NPC1 O15118 4/20 0.35
RAB9A P51151 4/20 0.35
PDGFRB P09619 1/20 0.33
PDGFRA P16234 1/20 0.33
CHRM1 P11229 1/20 0.33
MAPK14 Q16539 1/20 0.33
MEN1 O00255 2/20 0.31
KMT2A Q03164 2/20 0.31
KDM4E B2RXH2 2/20 0.31
LMNA P02545 2/20 0.31
MAPT P10636 2/20 0.31
GAA P10253 1/20 0.31
HPGD P15428 1/20 0.31
MAPK1 P28482 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
PRMT5 O14744 1/20 0.31
STIM1 Q13586 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30081471 0.74 ALDH1A1 (0.45) ALDH1A1HSD17B10PARP1CHRM1LMNA
SCHEMBL9853741 0.74 ALDH1A1 (0.45) ALDH1A1HSD17B10PRMT5OPRM1OPRL1
SCHEMBL928489 0.74 ALDH1A1 (0.45) ALDH1A1HSD17B10PARP1NPC1RAB9A
SCHEMBL115602 0.74 ALDH1A1 (0.45) ALDH1A1HSD17B10PRMT5OPRM1OPRL1
SCHEMBL659126 0.74 ALDH1A1 (0.45) ALDH1A1HSD17B10PRMT5OPRM1OPRL1
SCHEMBL115601 0.74 ALDH1A1 (0.45) ALDH1A1HSD17B10PARP1CHRM1LMNA
SCHEMBL5562354 0.74 ALDH1A1 (0.45) ALDH1A1HSD17B10PRMT5OPRM1OPRL1
SCHEMBL2093035 0.74 ALDH1A1 (0.45) ALDH1A1HSD17B10NPC1RAB9ACHRM1
SCHEMBL288616 0.74 ALDH1A1 (0.45) ALDH1A1HSD17B10PRMT5OPRM1OPRL1
SCHEMBL29806829 0.74 ALDH1A1 (0.45) ALDH1A1HSD17B10NPC1RAB9ACHRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250163079-A1 KRAS INHIBITORS INCYTE CORPORATION 2025-05-22 US claimed
US-10224485-B2 Process for preparing a crystalline organic semiconductor material BASF SE (DE) 2019-03-05 US claimed
US-20170012208-A1 ORGANIC SEMICONDUCTOR FORMULATIONS USINVEST LLC 2017-01-12 US claimed
US-20250171438-A1 COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS AGIOS PHARMACEUTICALS, INC. 2025-05-29 US disclosed
US-20250163079-A1 KRAS INHIBITORS INCYTE CORPORATION 2025-05-22 US disclosed
CN-119798326-A Benzothiazole phosphorus compound and synthetic method and application thereof 江西师范大学 2025-04-11 CN disclosed
US-20240140957-A1 BRIDGED COMPOUNDS AS KRAS G12D INHIBITOR AND DEGRADER AND THE USE THEREOF BEONE MEDICINES I GMBH (CH) 2024-05-02 US disclosed
EP-3183250-B1 PROCESS FOR PREPARING CRYSTALLINE ORGANIC SEMICONDUCTOR MATERIAL CLAP CO LTD (KR) 2023-10-04 EP disclosed
US-20230137250-A1 POLYMERIZABLE LIQUID CRYSTAL COMPOUND, POLYMERIZABLE COMPOSITION, POLYMER, RETARDATION FILM, METHOD FOR PRODUCING RETARDATION FILM, TRANSFER LAMINATE, OPTICAL MEMBER, METHOD FOR PRODUCING OPTICAL MEMBER, AND DISPLAY DEVICE DAI NIPPON PRINTING CO., LTD. (JP) 2023-05-04 US disclosed
US-20230137250-A1 POLYMERIZABLE LIQUID CRYSTAL COMPOUND, POLYMERIZABLE COMPOSITION, POLYMER, RETARDATION FILM, METHOD FOR PRODUCING RETARDATION FILM, TRANSFER LAMINATE, OPTICAL MEMBER, METHOD FOR PRODUCING OPTICAL MEMBER, AND DISPLAY DEVICE DAI NIPPON PRINTING CO., LTD. (JP) 2023-05-04 US disclosed
US-11560518-B2 Polymerizable liquid crystal compound, polymerizable composition, polymer, retardation film, method for producing retardation film, transfer laminate, optical member, method for producing optical member, and display device DAI NIPPON PRINTING CO., LTD. (JP) 2023-01-24 US disclosed
US-20140288081-A1 THERAPEUTIC COMPOUNDS AND COMPOSITIONS AGIOS PHARMACEUTICALS, INC (US) 2014-09-25 US disclosed
WO-2014139144-A1 THERAPEUTIC COMPOUNDS AND COMPOSITIONS AGIOS PHARMACEUTICALS, INC. (US) 2014-09-18 WO disclosed
WO-2014139325-A1 THERAPEUTIC COMPOUNDS AND COMPOSITIONS AGIOS PHARMACEUTICALS, INC. (US) 2014-09-18 WO disclosed
WO-2014139325-A1 THERAPEUTIC COMPOUNDS AND COMPOSITIONS AGIOS PHARMACEUTICALS, INC. (US) 2014-09-18 WO disclosed
WO-2014139144-A1 THERAPEUTIC COMPOUNDS AND COMPOSITIONS AGIOS PHARMACEUTICALS, INC. (US) 2014-09-18 WO disclosed
US-20140042369-A1 Organic Semiconductor Formulations USINVEST LLC 2014-02-13 US disclosed
EP-1006114-B1 PYRAZOLE DERIVATIVES AND COX INHIBITORS CONTAINING THEM GRELAN PHARMACEUTICAL CO (JP) 2003-01-22 EP disclosed
US-6136831-A ANTIINFLAMMATORY AGENTS, GASTROINTESTINAL AGENTS, ENZYME INHIBITORS GRELAN PHARMACEUTICAL CO., LTD. (JP) 2000-10-24 US disclosed
EP-1006114-A1 PYRAZOLE DERIVATIVES AND COX INHIBITORS CONTAINING THEM Grelan Pharmaceutical Co., Ltd. (JP) 2000-06-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230137250-A1 POLYMERIZABLE LIQUID CRYSTAL COMPOUND, POLYMERIZABLE COMPOSITION, POLYMER, RETARDATION FILM, METHOD FOR PRODUCING RETARDATION FILM, TRANSFER LAMINATE, OPTICAL MEMBER, METHOD FOR PRODUCING OPTICAL MEMBER, AND DISPLAY DEVICE TRRAP, CDH1, LRRFIP1 ALDH1A1 3729/4885HSD17B10 2972/4885PARP1 1450/4885
US-20140288081-A1 THERAPEUTIC COMPOUNDS AND COMPOSITIONS PDK1, PC, PDK2 ALDH1A1 860/4885HSD17B10 429/4885PARP1 1298/4885
US-11560518-B2 Polymerizable liquid crystal compound, polymerizable composition, polymer, retardation film, method for producing retardation film, transfer laminate, optical member, method for producing optical member, and display device TRRAP, CDH1, LRRFIP1 ALDH1A1 3729/4885HSD17B10 2972/4885PARP1 1450/4885
US-20250163079-A1 KRAS INHIBITORS KRAS, NRAS, HRAS ALDH1A1 2350/4885HSD17B10 3080/4885PARP1 730/4885
US-20240140957-A1 BRIDGED COMPOUNDS AS KRAS G12D INHIBITOR AND DEGRADER AND THE USE THEREOF KRAS, NRAS, G3BP1 ALDH1A1 3389/4885HSD17B10 4552/4885PARP1 529/4885
US-10224485-B2 Process for preparing a crystalline organic semiconductor material STOM, SPOP, TTR ALDH1A1 4757/4885HSD17B10 4363/4885PARP1 4793/4885
US-20250171438-A1 COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS PAH, KDM8, PHF8 ALDH1A1 865/4885HSD17B10 1477/4885PARP1 2718/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.